



(11) **EP 2 349 282 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**26.02.2020 Bulletin 2020/09**

(45) Date of publication and mention  
of the grant of the patent:  
**15.01.2020 Bulletin 2020/03**

(21) Application number: **09821103.0**

(22) Date of filing: **13.10.2009**

(51) Int Cl.:  
**A61K 31/7036** <sup>(2006.01)</sup> **A61P 11/00** <sup>(2006.01)</sup>  
**A61K 9/127** <sup>(2006.01)</sup> **A61K 47/44** <sup>(2017.01)</sup>  
**A61P 11/12** <sup>(2006.01)</sup> **A61P 31/04** <sup>(2006.01)</sup>  
**A61K 9/00** <sup>(2006.01)</sup> **A61K 31/375** <sup>(2006.01)</sup>  
**A61K 31/70** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2009/060468**

(87) International publication number:  
**WO 2010/045209 (22.04.2010 Gazette 2010/16)**

(54) **METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS**

VERFAHREN ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN MIT LIPOSOMALEN AMIKACINFORMULIERUNGEN

PROCÉDÉS DE TRAITEMENT DE TROUBLES PULMONAIRES PAR DES FORMULATIONS LIPOSOMALES D'AMIKACINE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL  
PT RO SE SI SK SM TR**

(30) Priority: **13.10.2008 US 250412**

(43) Date of publication of application:  
**03.08.2011 Bulletin 2011/31**

(73) Proprietor: **Insmmed Incorporated**  
**Bridgewater, NJ 08807-1704 (US)**

(72) Inventor: **GUPTA, Renu**  
**Moorestown, NJ 08057 (US)**

(74) Representative: **CMS Cameron McKenna Nabarro  
Olswang LLP**  
**Cannon Place**  
**78 Cannon Street**  
**London EC4N 6AF (GB)**

(56) References cited:

**US-A1- 2008 131 497**

- **MEERS P ET AL: "Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, OXFORD UNIVERSITY PRESS, GB, vol. 61, no. 4, 1 April 2008 (2008-04-01), pages 859-868, XP002632705, ISSN: 0305-7453, DOI: 10.1093/JAC/DKN059 [retrieved on 2008-02-27]**
- **RAMSEY B W ET AL: "INTERMITTENT ADMINISTRATION OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 340, no. 1, 7 January 1999 (1999-01-07), pages 23-30, XP001106341, ISSN: 0028-4793, DOI: 10.1056/NEJM199901073400104**
- **CLANCY J P ET AL: "Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.", THORAX SEP 2013, vol. 68, no. 9, September 2013 (2013-09), pages 818-825, XP002742980, ISSN: 1468-3296**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 349 282 B8**